Hepatitis B is a viral infection that affects the liver and can be both a short-term illness or a lifelong condition. Understanding when and how to get tested is crucial, as many people with the virus don't experience symptoms but can still spread the infection and face serious health risks over time.
Key points
check_circleAbout half of people with hepatitis B don't know they're infected because the virus often causes no symptoms, making testing essential for at-risk groups.
check_circleAll pregnant women must be tested at their first prenatal visit, as babies born to infected mothers have a 90% chance of developing chronic infection.
check_circleBlood tests that detect hepatitis B surface antigen (HBsAg) are the primary way to diagnose the infection and determine if it's acute or chronic.
check_circleRegular monitoring every six months can extend survival by more than one-third in people with chronic hepatitis B compared to no screening.
check_circleThe outdated term "healthy carrier" is misleading—people with chronic hepatitis B face nearly a 1 in 4 risk of serious liver complications even without symptoms.
check_circleClinical trials use specific diagnostic criteria including HBV DNA levels, liver enzyme tests, and liver damage assessment to qualify participants for new treatments.
check_circleNon-invasive tests like transient elastography (Fibroscan) can measure liver scarring without surgery, helping doctors assess disease progression.
check_circleInfants infected at birth are far more likely to develop chronic infection than adults, highlighting the importance of prevention and early diagnosis.
Introduction: Who Should Get Tested for Hepatitis B
Many people living with hepatitis B don't know they're infected because the virus often causes no symptoms at all. In fact, about 1 in 2 people with hepatitis B are unaware of their condition. This makes testing especially important, as the virus can be present in your body for years without you feeling sick, all while potentially causing liver damage.
You should consider getting tested for hepatitis B if you belong to certain groups at higher risk. If you were born in countries where hepatitis B is common—such as parts of Asia, Africa, South America, the Middle East, or the Caribbean—testing is advisable. The same applies if your parents were born in these regions, as the virus is often passed from mother to child during birth.
Testing is also recommended for people who inject drugs or share needles, those who live with or have sex with someone who has hepatitis B, and men who have sex with men. Healthcare workers who may be exposed to blood, people receiving dialysis, and those with certain chronic conditions like HIV, hepatitis C, or chronic liver disease should also seek testing.
All pregnant women need to be tested for hepatitis B at their first prenatal visit during each pregnancy. This is essential because if a mother has the virus, her baby can be infected during birth and is at very high risk of developing a chronic, lifelong infection. Babies infected at birth have about a 90% chance of the infection becoming chronic.
Even if you don't fit into any high-risk category, you can still ask your doctor about testing. If you've been exposed to someone else's blood or body fluids, if you've had unprotected sex with multiple partners, or if you've received tattoos or piercings with equipment that may not have been properly sterilized, testing can provide peace of mind and early detection if needed.
Diagnostic Methods for Hepatitis B
Diagnosing hepatitis B involves blood tests that look for specific markers of the virus. Your healthcare provider will perform a physical examination first, checking for signs of liver damage such as yellowing of the skin and eyes (called jaundice), stomach pain, or swelling in the abdomen. However, because symptoms are often absent, blood tests are the primary way to identify the infection.
The main blood test used to screen for hepatitis B looks for something called hepatitis B surface antigen, or HBsAg. This is a protein on the surface of the virus, and if it's found in your blood, it means you currently have a hepatitis B infection. This test can't tell you by itself whether your infection is acute (short-term) or chronic (long-term), but it's the starting point for diagnosis.
If the HBsAg test comes back positive, your doctor will order additional blood tests to learn more about your infection. These tests measure other markers in your blood, such as antibody to hepatitis B surface antigen (anti-HBs), which indicates immunity, and antibody to hepatitis B core antigen (anti-HBc), which shows past or current infection. Together, these markers help determine whether your infection is new, ongoing, or whether you've recovered and are now immune.
Another important blood test measures the amount of virus in your blood, known as HBV DNA levels. This test tells your doctor how active the virus is and helps guide decisions about whether treatment is needed. Higher levels of HBV DNA often mean the virus is actively replicating and may be causing more liver damage.
Your healthcare provider may also check your liver function by measuring levels of certain enzymes in your blood, such as alanine aminotransferase, or ALT. Elevated ALT levels can indicate that your liver is inflamed or damaged. This helps doctors understand how much harm the virus is causing to your liver.
In some cases, additional tests are needed to assess the extent of liver damage. A special type of ultrasound called transient elastography, sometimes known by the brand name Fibroscan, can measure the stiffness of your liver, which indicates scarring or fibrosis. More severe scarring is called cirrhosis, and this test helps doctors see how far liver damage has progressed without needing surgery.
A liver biopsy may be performed in certain situations. During this procedure, a thin needle is inserted through your skin and into your liver to remove a small tissue sample. This sample is then examined in a laboratory to check for damage or scarring. Although a biopsy provides detailed information, it's not always necessary, especially with the availability of non-invasive tests like elastography.
Regular liver ultrasounds are also used to screen for liver cancer, which is a serious complication of chronic hepatitis B. People with chronic infection, especially those with cirrhosis or a family history of liver cancer, should have ultrasounds every six months to catch any tumors early.
Diagnostics for Clinical Trial Qualification
When researchers conduct clinical trials to test new treatments for hepatitis B, they use specific tests to decide which patients are eligible to participate. These tests ensure that participants meet the criteria needed to evaluate whether a new drug or therapy is safe and effective.
Blood tests are central to qualifying patients for hepatitis B clinical trials. Researchers typically require confirmation that a person has chronic hepatitis B, which means the hepatitis B surface antigen (HBsAg) must be present in the blood for at least six months. This confirms the infection is long-term rather than a recent, acute case.
Trials often measure HBV DNA levels to determine how active the virus is in each participant's body. Many studies set minimum or maximum HBV DNA thresholds for enrollment, as they need to test treatments in people with varying levels of viral activity. For example, some trials might focus on people with very high viral loads, while others might include those whose virus is less active.
Liver function tests are also standard for trial qualification. Researchers check ALT levels and other liver enzymes to assess how much inflammation or damage is present. Some trials specifically enroll people with elevated ALT levels because these individuals have active liver inflammation and are more likely to benefit from new treatments.
Assessing the stage of liver damage is another key part of determining eligibility. Clinical trials may use elastography or liver biopsies to measure fibrosis and cirrhosis. Some trials are designed for people with early-stage disease, while others focus on those with advanced liver scarring. Knowing the stage of liver damage helps researchers understand whether a treatment works better at certain points in the disease's progression.
Additionally, trials may test for the presence of hepatitis B e antigen, or HBeAg, in the blood. This marker indicates higher levels of viral replication and infectiousness. Some treatments are specifically designed for people who are HBeAg-positive, while others target those who are HBeAg-negative, so testing for this marker is essential for sorting participants into the right groups.
Researchers also check for coinfections with other viruses like hepatitis C, hepatitis D, or HIV, as these can affect how hepatitis B behaves and how treatments work. Some trials exclude people with coinfections, while others are designed to study patients with multiple infections to see how treatments perform under more complex conditions.
Finally, participants must undergo tests to rule out other causes of liver disease, such as alcohol-related liver damage or autoimmune liver conditions. This ensures that any changes in liver health observed during the trial are due to hepatitis B and the treatment being tested, not other factors.
Prognosis and Survival Rate
Prognosis
The outlook for people with hepatitis B depends largely on whether the infection is acute or chronic, the extent of liver damage, and whether treatment is received. Most adults who get acute hepatitis B—about 95%—recover completely within six months and develop immunity that protects them for life. Their bodies successfully clear the virus, and they don't face long-term health problems from the infection.
However, the prognosis is different for chronic hepatitis B. People with chronic infection face ongoing risks because the virus remains in their body indefinitely. Without proper monitoring and treatment, chronic hepatitis B can lead to serious complications. About 25% of people with chronic hepatitis B will eventually develop cirrhosis, liver cancer, or liver failure. These outcomes can be life-threatening and significantly reduce quality of life.
The age at which someone becomes infected plays a major role in prognosis. Infants and young children who contract hepatitis B are much more likely to develop chronic infection—about 90% of infected infants and 30% of children infected between ages 1 and 5 will have lifelong infection. This is why preventing mother-to-child transmission through vaccination and screening during pregnancy is so critical.
Several factors affect how hepatitis B progresses and influence long-term outcomes. People with persistently high levels of the virus in their blood (HBV DNA), elevated liver enzymes, male sex, older age, and a family history of liver cancer face higher risks of serious complications. Coinfection with other viruses like hepatitis C, hepatitis D, or HIV can worsen liver damage and complicate prognosis. Alcohol use also accelerates liver damage in people with hepatitis B.
The good news is that proper monitoring and treatment can significantly improve outcomes. Antiviral medications can suppress the virus and reduce inflammation, which helps prevent cirrhosis and liver cancer. Studies have shown that treatment with antiviral drugs decreases the risk of developing serious liver disease and extends survival. Regular screening for liver cancer through ultrasounds every six months can catch tumors early when treatment is most effective.
Survival Rate
In 2022, hepatitis B resulted in an estimated 1.1 million deaths worldwide, mostly from cirrhosis and liver cancer. These deaths represent the most severe outcomes of chronic infection left unmonitored or untreated. However, survival rates vary widely depending on the stage of disease and access to care.
For people with chronic hepatitis B who receive regular monitoring and appropriate treatment, survival can approach that of the general population. One important study found that people with chronic hepatitis B who had six-monthly screening lived much longer—more than one-third longer—compared to those who received no screening. This underscores the life-saving value of consistent medical care and early detection of complications.
People who develop cirrhosis face more serious risks. Cirrhosis occurs when extensive scarring replaces healthy liver tissue, and this condition significantly affects survival. Once cirrhosis is present, the risk of liver failure and liver cancer increases substantially. However, even with cirrhosis, antiviral treatment can slow disease progression and improve outcomes.
Liver cancer is one of the most serious complications of chronic hepatitis B and is a leading cause of death in people with this infection. The risk of liver cancer remains even in people whose virus is suppressed with treatment, although the risk is lower compared to those not receiving treatment. Early detection through regular ultrasound screening greatly improves survival for those who develop liver cancer, as treatments are most effective when tumors are found small.
It's important to remember that chronic hepatitis B is a manageable condition. With proper medical care, lifestyle choices that protect the liver—such as avoiding alcohol and maintaining a healthy diet—and adherence to monitoring schedules, many people with hepatitis B live long, healthy lives. The key is staying engaged with healthcare, getting tested regularly, and starting treatment when recommended by your doctor.
lightbulb Did you know?
01The hepatitis B virus can remain infectious on surfaces for at least seven days, which is why blood tests are so critical for early detection even without symptoms.[7]
02About 90% of infants infected with hepatitis B at birth will develop chronic infection, compared to less than 10% of adults infected after age five, making early diagnosis in pregnancy vital.[6]
03One study found that people with chronic hepatitis B who had six-monthly screening lived significantly longer—more than one-third longer—compared to those who had no screening at all.[21]
Questions people often ask
info This guide is here to help you understand the condition. It does not replace a conversation with your doctor, who knows your situation best.
France
